Human marrow stromal cell therapy for stroke in rat: Neurotrophins and functional recovery

By Yi Li, Jieli Chen, X. Chen, Lei Wang, S. Gautam, Yong X. Xu, M. Katakowski, Li Zhang, Mei Lu, N. Janakiraman and 1 more. Neurology, 2002

922 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Autologous mesenchymal stem cell transplantation in stroke patients (2005, background): “Second, MSCs are eminently suitable for human trials because these cells can be obtained readily from bone marrow under local anesthesia, are easily expanded by culture, and potentially could be delivered to injured brain tissue without the need for invasive stereotaxic operations.(7) This is in con”
Why are MSCs therapeutic? New data: new insight (2009, background): “Last, Michael Chopp and others have reported that both direct injection or intravenous infusion of human marrow-derived and culture-expanded MSCs into rodent stroke models 1 week after interrupting blood flow to the brain results in the recovery of coordinate function by 6–8 weeks [43,44].”
Exosome-Mediated Transfer of miR-133b from Multipotent Mesenchymal Stromal Cells to Neural Cells Contributes to Neurite Outgrowth (2012, neutral): “MSCs escape immune system surveillance and survive in the CNS even after transplantation of allogeneic [81] or xenogeneic MSCs [52].”